Intelliscend Pharma Research And Consultancy Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 19-01-2025
- Paid Up Capital ₹ 0.10 M
as on 19-01-2025
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 36.49%
(FY 2023)
- Profit 143.18%
(FY 2023)
- Ebitda 1.51%
(FY 2023)
- Net Worth 34.57%
(FY 2023)
- Total Assets 3.31%
(FY 2023)
About Intelliscend Pharma Research And Consultancy
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Arti Potdar, Reena Roy, Sunilendu Roy, and One other member serve as directors at the Company.
- CIN/LLPIN
U74120MH2013PTC249826
- Company No.
249826
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Nov 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Intelliscend Pharma Research And Consultancy?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunilendu Roy  | Managing Director | 20-Nov-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Arti Potdar | Director | 06-Nov-2013 | Current |
| Reena Roy | Director | 06-Nov-2013 | Current |
| Shruti Roy | Director | 12-Feb-2021 | Current |
Financial Performance of Intelliscend Pharma Research And Consultancy.
Intelliscend Pharma Research And Consultancy Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 36.49% increase. The company also saw a substantial improvement in profitability, with a 143.18% increase in profit. The company's net worth Soared by an impressive increase of 34.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Intelliscend Pharma Research And Consultancy?
Unlock access to Intelliscend Pharma Research And Consultancy's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Intelliscend Pharma Research And Consultancy?
Unlock and access historical data on people associated with Intelliscend Pharma Research And Consultancy, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Intelliscend Pharma Research And Consultancy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Intelliscend Pharma Research And Consultancy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
